» Articles » PMID: 2448308

Locus of Inhibitory Action of CAMP-dependent Protein Kinase in the Antigen Receptor-triggered Cytotoxic T Lymphocyte Activation Pathway

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1988 Feb 15
PMID 2448308
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanism of the cAMP involvement in regulation of cellular functions was studied here using a novel functional assay (antigen receptor-triggered exocytosis of granules) of cloned cytotoxic T lymphocytes (CTL). We suggest that cAMP-dependent protein kinase, protein kinase A, counteracts the protein kinase C and Ca2+-mediated stimulatory T-cell antigen receptor (TcR)-triggered biochemical pathway. This suggestion is supported by experimental results which satisfy criteria for protein kinase A involvement in cellular functions. Pretreatment of CTL with cholera toxin induces cAMP accumulation in CTL, partially inhibits TcR-triggered "lethal hit" delivery to the target cell, and almost completely blocks TcR-triggered exocytosis of granules from CTL. Other agents that raise the intracellular level of cAMP, including forskolin and isobutylmethylxanthine (IBMX) also inhibit TcR-triggered CTL activation. Involvement of cAMP-dependent protein kinase in an inhibitory pathway is suggested by the synergistic effects of cyclic nucleotide analogs 8-bromo-cAMP and N6-benzoyl-cAMP in inhibition of TcR-triggered exocytosis. Forskolin and IBMX inhibited TcR-triggered phosphoinositide turnover in CTL, suggesting that cAMP affected very early events in signal transduction that follow TcR cross-linking by a ligand. The ability of IBMX to inhibit CTL activation when the TcR cross-linking step was by-passed by the combination of phorbol myristate acetate and ionophore A23187 suggests that the locus of inhibitory effect of cAMP is at both the early and late stages of the TcR-triggered transmembrane signaling pathway.

Citing Articles

Immune Features of Tumor Microenvironment: A Genetic Spotlight.

Asadi M, Zarredar H, Zafari V, Soleimani Z, Saeedi H, Caner A Cell Biochem Biophys. 2023; 82(1):107-118.

PMID: 37870699 DOI: 10.1007/s12013-023-01192-7.


Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.

Augustin R, Leone R, Naing A, Fong L, Bao R, Luke J J Immunother Cancer. 2022; 10(2).

PMID: 35135866 PMC: 8830302. DOI: 10.1136/jitc-2021-004089.


Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.

Tripathi A, Lin E, Xie W, Flaifel A, Steinharter J, Stern Gatof E J Immunother Cancer. 2020; 8(2).

PMID: 33177176 PMC: 7661372. DOI: 10.1136/jitc-2020-001467.


Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.

Steingold J, Hatfield S Front Immunol. 2020; 11:570041.

PMID: 33117358 PMC: 7553081. DOI: 10.3389/fimmu.2020.570041.


Blockade of adenosine A2A receptor enhances CD8 T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.

Ma S, Deng W, Liu J, Mao L, Yu G, Bu L Mol Cancer. 2017; 16(1):99.

PMID: 28592285 PMC: 5461710. DOI: 10.1186/s12943-017-0665-0.